• Home
  • »
  • About Alexion
Share, Send, or Save

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.

Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Our breakthrough products

Alexion developed Soliris® (eculizumab), the world's first approved terminal complement inhibitor, from the laboratory through commercialization.

Today, Soliris is approved in nearly 50 countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and in more than 40 countries for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) — two life-threatening, ultra-rare disorders caused by uncontrolled complement activation.

As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders.

Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders: Strensiq® (asfotase alfa) is approved for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) is approved for patients with lysosomal acid lipase deficiency (LAL-D).

A global leader in rare diseases 

Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012. Our global headquarters and research operations are in New Haven, Conn. Alexion's approximately 3,000 employees around the world serve patients in 50 countries.

As we continue to expand our operations to serve more patients in additional countries, Alexion has emerged as one of the world's leading rare disease companies. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities.


Our Values

At Alexion, we see opportunities where others do not. We have the courage to explore what is believed to be impossible, and to create what hasn't been imagined. We are driven to take on devastating diseases, and settle for nothing short of transformational change because we know patients' lives are at stake.

Our three values—Find Answers, Change the World, and Create a Legacy—guide our commitment to transforming the lives of patients with rare and devastating diseases. Our values also guide our philanthropic endeavors as we strive to make a meaningful impact as a global corporate citizen.

Read More About Our Corporate Giving

Find Answers

We hold ourselves accountable for finding the most elusive answers to transform lives. We have the courage to ask daunting questions and the stamina to overcome failure. We champion our patients and each other, providing solutions when others cannot. Together, we can achieve the impossible.

Change the World

We deliver nothing less than transformation so that, together with our patients, we change the world. We engineer our own path because the scientific challenges we choose to tackle require it. We power innovation to such a degree that we define the future.

Create a Legacy

Our pursuit to help the families affected by rare and devastating diseases pushes the boundaries of what science can offer to create lasting impact. Our legacy will be measured in the families we serve today and the generations that follow. We will leave no one behind.